SMPD3 and metabolic syndrome: Since excess ceramide production causes lipotoxicity, metabolic dysregulation and atherogenesis, dual targeting of both DES1 and Smpd3/nSMase2 may be a novel strategy for treatment of metabolic syndrome and importantly deadly co-morbidities.